eligibility_summary
Inclusion: consent, age 18–75, ECOG 0–1, life expectancy ≥12 weeks, ≥1 measurable lesion (RECIST 1.1), effective contraception to 6 months post–last dose, negative pregnancy test ≤7 days before first dose for WOCBP. Exclusion: major surgery/trauma ≤4 weeks or planned surgery, immunomodulators ≤14 days, systemic steroids/immunosuppressants ≤14 days (except local/short-term), active IV-treated infection, HIV/immunodeficiency, pregnant/lactating, poor compliance.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase Ib/II study in first-line advanced neuroendocrine carcinoma tests: 1) LBL-024 (investigational immunotherapy, specific target not disclosed) plus etoposide and platinum (cisplatin or carboplatin), and 2) reference arm atezolizumab + etoposide + carboplatin. Drug types/mechanisms: Etoposide is a cytotoxic topoisomerase II inhibitor causing DNA strand breaks, cisplatin/carboplatin are platinum chemotherapies forming DNA crosslinks, atezolizumab is an anti–PD-L1 monoclonal antibody (immune checkpoint inhibitor) blocking PD-1/PD-L1 to restore T-cell antitumor activity. Targeted cells/pathways: tumor cell DNA replication/repair (Topo II, DNA crosslink repair) and the PD-1/PD-L1 immune axis on tumor and immune cells. LBL-024’s precise mechanism/pathway is not specified in the registry.